Alibaba, Zoom Video And 76 Biggest Movers From Yesterday
Gainers
Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media.
Can-Fite To Submit FDA & EMA Registration Plans For Piclidenoson In The Oral Treatment Of Moderate To Severe Psoriasis
Further analysis of Phase III COMFORT™ data show Piclidenoson's superior safety profile and higher patient compliance compared to Otezla®
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI), a
Akerna Shares Dip 53%, Here’s 78 Biggest Movers From Yesterday
Gainers
Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.
The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Can-Fite Announces Phase III COMFORT Study Met Primary Endpoint
Phase III COMFORT™ study met its primary endpoint with statistically significant improvement and Piclidenoson had an excellent safety profile
Can-Fite has licensing deals for the marketing of Piclidenoson for
Can Fite Biofarma: Q1 Earnings Insights
Can Fite Biofarma (AMEX:CANF) reported its Q1 earnings results on Thursday, May 26, 2022.
Here's what investors need to know about the announcement.
Can-Fite Q1 Revenue Increases 38.5%, Phase III Psoriasis Treatment Study Results Expected In Q2
Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE: CFBI) released financial results for the quarter ended March 31, 2022, revealing revenue of $200,000, an increase of or 38.5%, compared to $150,000 in Q1 2021.
Q1 Financial Highlights
Can-Fite Reports Revenue Growth In 2021, Provides Clinical Update
Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI) announced financial results for the year ended December 31, 2021.
The company said that it had $18.9 million in cash, cash equivalents, and short-term deposits, on December 31, 2021.
Can-Fite To Reveal Findings In Treatment Of Liver Cancer And Fibrosis With Cannabinoids At CannX
Dr. Pnina Fishman CEO of Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE: CFBI) will deliver a poster presentation titled “Inhibition of Hepatocellular Carcinoma Growth and Liver Fibrosis by Nanomolar Cannabinoids Concentrations” at the CannX Medical Cannabis Conference in Tel Aviv which takes place March 14 – 15, 2022.
